Diffuse intrinsic pontine glioma (DIPG) is the most common and deadliest pediatric brainstem tumor and is difficult to treat with chemotherapy in part due to the blood-brain barrier (BBB). Focused ultrasound (FUS) and microbubbles (MBs) have been shown to cause BBB disruption (BBBD), allowing larger chemotherapeutics to enter the parenchyma. Panobinostat is an example of a promising in vitro agent in DIPG with poor clinical efficacy due to low BBB penetrance. In this study, we hypothesized that using FUS to disrupt the BBB allows higher concentrations of panobinostat to accumulate in the tumor, providing a therapeutic effect. Mice were orthotopically injected with a patient-derived DMG cell line, BT-245. MRI was used to guide FUS/MB (1.5 MHz, 0.615 MPa PNP, 1 Hz PRF, 10 ms PL, 3 min treatment time) / (25 uL/kg, IV) targeting to the tumor location. In animals receiving panobinostat (10 mg/kg, IP) in combination with FUS/MB, a 3-fold increase in tumor panobinostat concentration was observed, with only insignificant increase of the drug in the forebrain. In mice receiving three weekly treatments, the combination of panobinostat and FUS/MB led to a 71% reduction of tumor volumes by MRI (p = 0.01). Furthermore, FUS/MB improved the mean survival from 21 to 31 days (p < 0.0001). Our study demonstrates that FUS-mediated BBBD can increase the delivery of panobinostat to an orthotopic DMG tumor, providing a strong therapeutic effect and increased survival.
Diffuse intrinsic pontine glioma is the most common and deadliest pediatric brainstem tumor and is difficult to treat with chemotherapy in part due to the blood-brain barrier (BBB). Focused ultrasound (FUS) and microbubbles (MBs) have been shown to cause BBB disruption (BBBD), allowing larger chemotherapeutics to enter the parenchyma. Panobinostat is an example of a promising in vitro agent in DIPG with poor BBB penetrance. In this study, we hypothesized that using FUS to disrupt the BBB allows higher concentrations of panobinostat to accumulate in the tumor, providing a therapeutic effect. Mice were orthotopically injected with a patient-biopsied DIPG cell line, BT-245. After two weeks of growth, MR images guided FUS targeting to the tumor location. Microbubbles (25µl/kg, IV) and FUS (Frequency: 1.515 MHz, PNP: 0.77MPa, PRF: 1Hz, PL: 10ms, treatment time: 3 minutes) were applied to half the mice. Passive cavitation data (PCD) was collected and analyzed. Panobinostat was given (10mg/kg IP) to all mice. After 1.5 hours, a subset of mice were sacrificed to determine the concentration of panobinostat in tumor and cortex areas. We showed a 3-fold drug concentration increase in the tumor region while only slightly increasing the concentration in the forebrain. The remaining mice received three weekly treatments. Half were treated with FUS/MB and panobinostat, while others received panobinostat only. MRI was taken weekly to evaluate BBBD extent and tumor growth. PCD during treatments showed ideal cavitation of microbubbles illustrating safety and consistency across all treatments. The combination of panobinostat and FUS exhibited a tumor size decrease of 71% on MRI compared to panobinostat alone. Furthermore, FUS/MB improved the mean survival from 21 to 31.5 days (p=0.0001). Our study demonstrates that FUS-mediated BBBD can increase the delivery of panobinostat to an orthotopic DMG tumor, providing a strong therapeutic effect and increased survival.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.